Shared on30 Jul 25Fair value Increased 12%
The significant upward revision in Tatva Chintan Pharma Chem’s consensus price target reflects sharply improved net profit margins and a substantial reduction in forward P/E, supporting a new fair value estimate of ₹833.67. What's in the News Board meeting scheduled to consider and approve unaudited financial results for the quarter ended 30 June 2025.
Shared on15 Jul 25Fair value Decreased 35%
A sharp decline in net profit margin alongside a surge in future P/E indicates worsening profitability and a more expensive valuation, justifying the substantial reduction in Tatva Chintan Pharma Chem's fair value price target from ₹1139 to ₹742. WHAT'S IN THE NEWS Received an export order worth USD 3.56 million (INR 299.5 million) for Specialty Chemicals under the Pharma & Agro Intermediates & Speciality Chemicals category, to be delivered in Q3 FY26.
Shared on01 May 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 0.78%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 10%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.